RADIOSO MILAN I (RADar Reflector localisatiOn-SCOUT for carcinOma Mammae, the MILAN IEO Experience I)

Last updated: August 2, 2024
Sponsor: European Institute of Oncology
Overall Status: Active - Recruiting

Phase

N/A

Condition

Carcinoma

Cancer

Breast Cancer

Treatment

SCOUT® Radar occult breast lesion Localization

Clinical Study ID

NCT05963464
IEO 1911/
  • Ages 18-90
  • Female

Study Summary

This is a monocentric prospective observational study for patients with clinical undetectable breast lesions and indications to breast conserving surgery for histological characterization.

The SCOUT® Radar occult breast lesion Localization (SRL) consists of an implantable reflector, a detector handpiece and a console and it uses non-radioactive micro-impulses to guide surgical excision in real time.

The study describes the experience with 300 patients at the European Institute of Oncology.

The primary endpoints of the study are the rates of successful positioning, localization and recovery of the reflector SRL.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Diagnosis of nonpalpable breast or lymph nodes

  • Patients referred to IEO for breast surgery

  • Patients between 18 and 90 years old

  • Female patients

  • Conservative surgery

  • Patients willing and able to follow the study procedures and available for follow-upover the entire duration of the study

Exclusion

Exclusion Criteria:

  • Patients known or suspected to be allergic to materials similar to those in the SAVISCOUT components (nickel)

  • Any condition that may expose the individual to a higher risk or preclude the studyfrom achieving full compliance or completion.

Study Design

Total Participants: 300
Treatment Group(s): 1
Primary Treatment: SCOUT® Radar occult breast lesion Localization
Phase:
Study Start date:
February 01, 2023
Estimated Completion Date:
December 31, 2024

Study Description

It has been estimated that 31,8% of breast cancer patients undergo pre-operational lesion localization. Of them, 19% have been previously administered neoadjuvant chemotherapy (NACT). Based on retrospective data, NACT administration is believed to steadily increase by 1,3%, each year.

The IEO Breast Division Program aims at improving the treatment and planning options available to patients referred for radio guided breast surgery.

At IEO, ROLL remains the standard of care. From its inception 25 year ago to the present day,the investigators have gained significant expertise and now perform more than 1000 procedures per year.

The investigators believe that SRL (SCOUT® Radar occult breast lesion Localization) could be added to the procedure of reference in the following cases, still under investigation, where it seems to present some advantages when compared to ROLL:

  1. Long-term positioning of the reflector, as in the case of patients undergoing neoadjuvant treatment

  2. Reflector placement in malignant lymphadenopathy prior to neoadjuvant chemotherapy

  3. Placement of multiple reflectors, or use of both SRL and ROLL in patients with multifocal or multicentric neoplasia referred for conservative surgery

  4. BI-RADS 5 patients suspected for ductal carcinoma in situ (DCIS) and eligible for conservative surgery, could undergo reflector placement after vacuum-assisted breast biopsy (VABB) and also be scheduled for Monday morning surgery

  5. Placement of the reflector using MR-compatible introducer needles

Connect with a study center

  • European Institute of Oncology

    Milan,
    Italy

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.